Joycelyn Jie Xin Lee

National University of Singapore — Singapore

Medicine · Health Sciences

15h-index1.1kcitations66works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(22), Cancer Immunotherapy and Biomarkers(18), Pancreatic and Hepatic Oncology Research(7), Liver Disease Diagnosis and Treatment(7), Colorectal Cancer Treatments and Studies(7)

Publications66 total

Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis
Liver Cancer·2025Open Access
Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials
Surgery·2025
The impact of socioeconomic status with overall survival in hepatocellular carcinoma: a systematic review and meta-analysis
ESMO Gastrointestinal Oncology·2025Open Access
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer
ESMO Open·2025· 1 citedOpen Access
60P Longitudinal dynamics of the gut microbiome and dietary associations in immunotherapy-treated hepatobiliary cancer patients
ESMO Open·2025Open Access
2343P The association of socioeconomic status with overall survival in hepatocellular carcinoma: A systematic review & meta-analysis
Annals of Oncology·2025
49P Dietary carbohydrate intake shapes gut microbial features associated with immune checkpoint inhibitor (ICI) outcomes in hepatocellular (HCC) and cholangiocarcinoma (CCA) patients
ESMO Open·2025Open Access
Targeting Treg–fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma
Gut·2025· 6 citedOpen Access
COSMIC-312: lessons learned from another combination immune checkpoint and multi-kinase inhibitor trial
AME Clinical Trials Review·2025
ASO Visual Abstract: Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer—Systematic Review and Meta-analysis of Latest Randomized Controlled Trials
Annals of Surgical Oncology·2025
Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Controlled Trials
Annals of Surgical Oncology·2025· 6 cited
The Association of Socioeconomic Status with Overall Survival in Hepatocellular Carcinoma: A Systematic Review & Meta-Analysis
SSRN Electronic Journal·2025Open Access
First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
SSRN Electronic Journal·2025Open Access
Impact of Antibiotics and Chronic Medications on Efficacy of Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
Asia-Pacific Journal of Clinical Oncology·2024· 3 citedOpen Access
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific
Targeted Oncology·2024· 4 cited
Delayed Immune Checkpoint Inhibitor-Induced Acute Tubulointerstitial Nephritis (ICI-ATIN) Relapse with Proton-Pump Inhibitor Re-exposure Despite ICI Discontinuation: A Case Report
Journal of the American Society of Nephrology·2024· 1 cited
Sequential Development of Immune Checkpoint Inhibitor-Induced Acute Tubulointerstitial Nephritis (ICI-ATIN) following Stevens-Johnson Syndrome (SJS)-Like Reaction in Patient on Pembrolizumab and Meropenem: A Common Drug Trigger?
Journal of the American Society of Nephrology·2024· 1 cited
Feasibility study utilizing a combinatorial functional precision medicine platform, Optim.AI, to help guide treatment for pancreatic cancer.
Journal of Clinical Oncology·2024· 1 cited
Single-cell and spatial atlas of steatotic liver disease-related hepatocellular carcinoma
2024· 1 citedOpen Access
Hyperacute Immune Checkpoint Inhibitor-Associated Acute Tubulointerstitial Nephritis (ICI-ATIN) Followed by ICI-Renal Tubular Acidosis (RTA): A Case Report
Journal of the American Society of Nephrology·2023· 1 cited
page 1 of 4Next →

Frequent Co-authors

Su Pin Choo(24), David Tai(22), Han Chong Toh(9), Kennedy Yao Yi Ng(9), Sze Huey Tan(8), Brian K. P. Goh(8), Tony Kiat Hon Lim(8), Joe Yeong(8), Pierce K. H. Chow(7), Valerie Chew(7), Wai Meng David Tai(6), Suat Ying Lee(6), Alexander Yaw Fui Chung(5), Weiwei Zhai(5), Wei Qiang Leow(5), Andrea Jing Shi Ang(5), Lawrence Wen Jun Wong(5), Kelvin Siu Hoong Loke(4), Apoorva Gogna(4), Tiffany Hennedige(4)